依普利酮的价格

(Inspra) is used for the treatment of essential hypertension and heart failure after myocardial infarction. Its aldosterone antagonism is stronger than that of spironolactone, and its affinity for androgen and progesterone receptors is extremely low. It has few adverse reactions. It has a positive therapeutic effect in the treatment of hypertension, heart failure and myocardial infarction, and is well tolerated. It is a good alternative to spironolactone.

Without damaging the organs, eplerenone (Inspra) has a protective effect on the liver, heart disease, and kidneys. Not only that, it can also promote urination without losing potassium. Eplerenone also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.

Eplerenone (Inspra) has significant therapeutic effects and relatively high safety. It has attracted widespread attention once it was launched. In addition to its effects, the price of eplerenone is also a focus of attention for everyone. Let’s take a look at the price of eplerenone.

Since it has not yet been launched in China, this drug is currently unavailable in China, and the price of the original drug in the United States is relatively high. Domestic patients may wish to purchase the Indian version of eplerenone, which is cheaper. The Indian version of eplerenone (Inspra) is produced by India's Lupine Pharmaceuticals. The price is much lower than the original drug in the United States, and the effect is almost the same. The Indian version of eplerenone has a specification of 50mg*100 tablets and a price of around $500. Due to the influence of exchange rates and other factors, the price is not fixed. Please consult Medical Travel for specific prices.

Recommended related hot articles: /newsDetail/73002.html